Echo Therapeutics begins trading on the Nasdaq today Print E-mail
By Staff and Wire Reports   
Wednesday, 29 June 2011 08:25
penny stockShare of Echo Therapeutics, Inc. (NASDAQ: ECTE) rose nicely after they announced yesterday that its common shares have been approved for listing on the NASDAQ Capital Market.

Echo Therapeutics' wireless glucose-monitoring system presents opportunity in diabetes market

Expert Briefing: What Investors Should Know About Tight Glycemic Control and Its Future

Echo is a company we've been covering in recent weeks. They are developing a needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery.

Echo expects its shares to begin trading on NASDAQ today- Wednesday, June 29, 2011. The company plans to continue to trade under the ticker symbol "ECTE."

"The move to NASDAQ is a significant milestone for Echo and underscores our commitment to grow the value of our company and strengthen our shareholder base," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "As we continue to build on the positive momentum generated throughout this year, we are very pleased to begin trading on NASDAQ and believe it will provide more liquidity for our current stockholders and increase visibility to the investment community.  We anticipate being able to leverage the strong fundamentals of the Company with the increased visibility that NASDAQ will provide in order to maximize shareholder value over the short and long-term."

"We welcome Echo Therapeutics, Inc. to the NASDAQ family of listed healthcare companies," commented Robert H. McCooey, Jr., Senior Vice President of New Listings and Capital Markets, NASDAQ OMX.  "Echo embodies the strategic vision and innovative thinking that characterizes our listed companies. We congratulate Echo on its listing on the NASDAQ Capital Market and look forward to supporting their continued success."



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter